July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Clinical Outcomes and Higher Order Aberrations after Combination Intracorneal Ring Segments and Corneal Collagen Crosslinking
Author Affiliations & Notes
  • Steven A Greenstein
    Cornea and Laser Eye Institute, Teaneck, New Jersey, United States
    Ophthalmology, Rutgers University - New Jersey Medical School, New Jersey, United States
  • Lauren Rosato
    Cornea and Laser Eye Institute, Teaneck, New Jersey, United States
  • Peter Hersh
    Cornea and Laser Eye Institute, Teaneck, New Jersey, United States
    Ophthalmology, Rutgers University - New Jersey Medical School, New Jersey, United States
  • Footnotes
    Commercial Relationships   Steven Greenstein, None; Lauren Rosato, None; Peter Hersh, Avedro INC (C), Peschke Trade GmbH (C)
  • Footnotes
    Support  Research to Prevent Blindness
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2220. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Steven A Greenstein, Lauren Rosato, Peter Hersh; Clinical Outcomes and Higher Order Aberrations after Combination Intracorneal Ring Segments and Corneal Collagen Crosslinking. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2220.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the clinical outcomes and corneal higher order aberrations (HOA), 6 months after implantation of Intacs,® followed by corneal collagen cross-linking (CXL) therapy for keratoconus.

Methods : Patients were enrolled as part of a prospective, randomized, controlled clinical trial, and were randomized to one of two groups: Intacs placement, immediately followed by CXL during the same session, or Intacs placement followed by crosslinking 3 months later. This study was a secondary analysis performed on the changes of total, trephoil 0, trephoil 30, coma 0, coma 90, and spherical higher order aberrations, 6 months after combination therapy (Pentacam,Oculus Inc, USA). The data was compared using a paired two tailed t test (significant, P<0.05).

Results : Sixty two eyes (62 patients) underwent cobination therapy. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), maximum keratometry (Kmax), IS ratio (IS), and the point of maximum flattening(Kflat) all improved 6 months after therapy [( UDVA-0.2+/-0.31p<0.01), ( CDVA-0.1+/-0.2,p<0.01),(Kmax-3.2D+/-3.1D,p<0.01),(IS-5.1D+/-6.4D, p<0.01), (Kflat-7.9D+/-4.3D)]. Preoperative total, trephoil 0, trephoil 30, coma 0, coma 90, and spherical aberrations (root mean square) were 4.0+/-1.9, 0.6+/-0.5, 0.5+/-0.5, 1.1+/-0.9, 3.2+/-1.8, and 0.9+/-0.9, respectively. Total, coma 0, and coma 90 HOAs significantly improved by 1.2+/-0.7(p<0.01), 0.37 +/-0.54(p<0.01), and 1.6+/-1.1(P<0.01), respectively. Trephoil 0, trephoil 30, and spherical aberrations changed by 0.01+/-0.6, 0.2+/-0.9, and 0.1+/-0.5, respectively. However, these changes failed to reach statistical significance (ptrephoil 0=0.9, ptrephoil 30=0.2, pspherical=0.1). The improvement in total HOAs correlated with flattening of Kmax and the point of maximum flattening [(rKmax= 0.3,p=0.03), rflat=0.4,p<0.01)]. The improvement of coma 90 was correlated with the Kflat alone (p=0.3,p=0.01).

Conclusions : UDVA, CDVA, Kmax, IS, and the Kflat improved, 6 months after Intacs and CXL therapy. Total, horzontal coma, and vertical coma higher order aberrations improved during this same time period as well. The Kflat significantly correlated with the improvement of both total and vertical coma HOAs. Flattening of Kmax correlated with the improvement of total HOAs, at 6 months, as well.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×